Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for your perspective. I appreciate when people have a reasonable perspective that is balanced and I agree 100% with your statement of,"A corporation with no capital or reserves that generated $4 million in revenues under Damaj is pretty impressive."
It will be interesting to see where this stock goes. I got out of it a while ago but looking to enter back in. I am hoping to pick some up in the 8's but we will see as this stock has been a roller coaster.
Or they can make soap out of it like Fight Club :/
Once you have hard evidence instead of soft evidence I would be interested in seeing what you have to offer. All that is publicly know does not support your statement. Why don't you give us a timeline when you think you will have the hard evidence?
Absolutely, from my perspective I see it trading in a tight range for a bit until all those things happen.
Thank you for a thoughtful response and have a great Friday!
I feel the audit will be the only real catalyst for this stocks PPS. Once that hurdle is jumped then I think objectively we can really take apart the company based off it's business lines. It's an unfortunate burden but a reality for this company due to the murky history of some.
I do think we will see a move back into the 3's which is where I got in, out, and in again. I was planning to pick more up down here tomorrow but I think the ride up is coming sooner than I had predicted.
Ironically, I am just citing whats available and looking into these folks myself but since you enjoy being pompous trying to engage in an adult like conversation may be lost with you.
Times2Times2
You may find this interesting:
https://www.cdc.gov/hiv/statistics/overview/geographicdistribution.html
Florida has one of the highest rates of HIV diagnosis here in the US.
and here by county in Florida:
https://aidsvu.org/state/florida/
The rate is almost 1 per 100 which is staggering.
Just to response to your question:
Of course this is all anecdotal and I am unaware of how be practices medicine-
http://drhbf.org/about_dr_bansal.php
Raised in Rudrapur, Dr. Himanshu Bansal completed his medical school residency and post graduation from King George Medical College in Lucknow, U.P. During his post graduation, he actively pursued work focused on spinal cord injury and after having subsequently presented his work at variety of forums, he decided to enrich himself in Hip and Knee replacement at Aarhus University Hospital at Denmark, Hip replacement unit of Guy's Hospital of Kings College at London and Orthopaedic Traumatology unit of Wurzburg university hospital at Germany & microsurgery at Osaka city university Japan.
Because of his interest for Striving excellence in management of spinal cord injury decided to work exclusively for spinally injured, he undertook various visits at:
Miami Project to Cure Paralysis (Miami University) USA.
Reeve-Irvine Research Center, California USA.
Queen Elizabeth Spinal Trauma Centre, Glasgow,
Scotland.
Neuroscience Center-Rutgers University USA.
Egaz Monis hospital, lisbon , Portugal.
European spinal cord research institute, Brescia Italy.
In one of his quests for treatments for Spinal Cord Injury worldwide, he got an insight on stem cell application in Spinal Cord and Neurological disorders. This was followed by various visits at the Institute of experimental medicine Prague, Beatson Institute, university of Glasgow and Saint Gerkatuen Hospital, Germany.
He has developed MRI based classification of Spinal cord injuries and developed a comprehensive treatment with autologous tissue like BM stem cells, dural nerve graft, nasal olfactory tissue and omental transposition after assessment of type and severity of SCI on MRI.
He has built a charitable hospital for orthopedic traumatology at Rudrapur, Uttrakhand, providing charitable treatment to poor masses and also established the first microsurgery unit of the state. He has been successful at inventing new types of cost effective implants to aid in successful fracture surgery outcomes like the patented forearm interlocking nail, locked nail for fracture of lower end radius.
He is currently developing a facility of Institute of Spinal Injury & Stem Cell Research at Rudrapur. Currently, he works Pan India in the following capacities as:
Scientist Spinal Cord, Neurodegenerative Disorders & Stem Cell Therapy
Institute of Spinal cord Injury, Rudrapur
Mother Cell STEM CELL RESEARCH & SOLUTIONS
Uttrakhand New Delhi Chennai
Consultant Orthopaedic Surgeon & Traumatologist
Anupam Hospital Rudrapur
Prof. Department of Orthopaedic Surgery
C.H. Medical College Kumaon University
Consultant Implant Development Research
Treu-Instrumente GmbH, Germany
Also, if you have ever been to India that is what all the clinics look like. Having traveled abroad multiple times and unfortunately having the need to visit ED/clinics, the reality is not everywhere is nice like our costly hospitals.
The Journal, "Nature" has an excellent write up based on where a medication is in the pipeline. I will link two articles below for your future reference.
P2 to P3 gives it a 16% chance of approval (Without modifiers from RAT or ANDA type additions)
From P3 to NDA is a 50% chance of approval.
http://www.nature.com/nbt/journal/v32/n1/box/nbt.2786_BX2.html
http://www.nature.com/nbt/journal/v32/n1/extref/nbt.2786-S1.pdf
A second article I also have looked into when investing in these types of stocks can be found here:
https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf
This is a very comprehensive assessment based on the type of drug, the disease they are trying to treat, and other modifiers. They both have different statistical variations and I tend to be more conservative with my estimates as well.
I hope everyone find these helpful and help make sound investment.
GLTA I appreciate your insights on the board.
I will try to always add something educational when I post :)
I agree with you 100% I am just cheap. It's in my blood haha!
I may have missed the boat to load up on 100k shares. Hopefully we get a dip next week :)
Thank you for the welcome. I have already initiated a small position with my "risk" money. I am newer to investing and have done well on the regular exchanges and not so well on the pinks, go figure right.
I am looking forward to seeing the supportive documentation in regards to this company. As with all biotech stocks they are a high risk/reward situation however I am still trying to parse through what changes have occurred that will give this company a chance of not going bankrupt soon.
Thanks again!
Thank you, I have familiarized myself with those website. I am going to shuffle through my academic databases to see if I can dig anything up later this week that brings more insights into the work they are doing.
Do you have evidence of this? I been trying to track this down and maybe I somehow missed it. NDA application or a Biologic application? Do they have any official submission on record? I am new here and trying to do some more DD however it's been a challenge to dig up anything.
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/
https://www.fda.gov/BiologicsBloodVaccines/ResourcesforYou/Consumers/default.htm
I do see stuff from "Bioheart" in 2015
https://www.fda.gov/downloads/aboutfda/workingatfda/ethics/ucm434422.pdf
Usually trials and the agents being introduced are public information and I can't seem to find any :(
I like to imagine I am lol
I appreciate everyone's informative responses. I been fortunate enough to make a little dough to put into technologies that I feel will really advance health among people. I wish between grad school, working full time, and other obligations I could invest more time into researching the science and companies. Thankfully we have a nice mix of people who are for and against these companies so I can be judicious on my investments when they are in the pinks. SEC companies have much more readily available information fortunately.
Pistol Pete near the end of March I will be joining you. I hope to pick up another 100k shares depending on the share price. I will link once it's processed. Hopefully the IND submission will hold off until then! Haha!
It appears the conference call provided enough assurance that there is support building. It closed strong on a red day in the US markets. I imagine we will see a pop tomorrow and test out 78 cents.
I am new to this stock but given the background information I have found seems a solid investment. I assume there are more like me buying into the stock and forgetting about it leaving less shares out there in the wild.
GLTA
Nice to see you here Soldier! Good luck to you! This company is fascinating as I picked up a small position. I need to move some money to invest more but I am hoping this has as much potential as I think it does.
Overall it is about what I expected. I imagine better numbers next quarter as the kinks get worked out with their other business line.
GLTA
What an excellent and thoughtful write up. Thank you for spending the time to put that all down here.
A
What did Drumpf say this time?
I agree with you 100%
I am reviewing their 10Q as well. I am not impressed what I am finding in their however I do know the science behind the tech and it's spot on.
My next DD needs to focus on the trials. Between all the cheer leading going on it's hard to see any conversations using what facts are in the wild. While I think you have a strong negative slant you at least provide strong evidence to support your statements.
It appears it's slowly retracting back to lower lows. The settlement only appears to have gave it a small bump and now is retracting back to it's normally traded area.
You are correct. This puts the company in an excellent position to continue their business plan. The contracts they have in place now help put the emphasis this will continue to grow like we all expect it to even without ANDA approval. I bet though it will get approved within the next 2 months based off of when they submitted it:
Time to ANDA Approval
Another semi-myth worth dispelling from the NPR piece is that “the median time it takes for the FDA to approve a generic is now 47 months.”
When viewed alongside the 10-month approval time for new drugs, that 47 months seems astounding.
But as FDA’s Janet Woodcock has explained to congressmen, that 47 month figure includes ANDAs lingering since before the first year of GDUFA.
What’s more is that the median time to market has fallen considerably as GDUFA has progressed. For the fastest 5% of ANDAs approved under GDUFA, the median approval time has gone from about 24 months in FY 2013 to less than 15 months in FY 2015.
Under the next iteration of GDUFA, which will take effect in FY2018, ANDA standard review time will likely be 10 months from submission and priority review would be eight months from submission. Compare those with the 42- to 44-month average approval time prior to GDUFA and it’s easy to see why FDA can be sensitive to criticism that GDUFA is not working.
However, ANDA submissions do continue to outpace approvals and criticism of the median approval times does seem warranted when considering that it takes FDA only 10 months to review and approve much more complex new drug submissions.
As RBC notes, “We have just begun to see [ANDA] approvals begin to meaningfully ramp and as this continues we expect that annual approvals will outpace submissions which in effect will begin to reduce ‘backlog’ whether defined as ANDAs at FDA or otherwise.”
- See more at: http://www.raps.org/Regulatory-Focus/News/2016/11/01/26106/Generic-Drug-Backlog-at-FDA-A-Dive-Into-the-Confusing-Numbers/#sthash.kio6UZ3D.dpuf
What do we think it's going to open at? I jumped out and now I may be chasing it!
Full year financials will be released on March 31st. A conference call will be held Monday April 3rd at 8:00 am Pacific Time.
The dial in number for the call will be on the March 31st news release.
A statement regarding the Alberta facility may be available on or before April 3rd . Further information should be in the notes to the financials.
Very true, I really appreciate you informing me about that company too. I wanted to say thanks. It appears they had a fire at one of their facilities and it's at a total loss however it was fully insured:
EWS RELEASE
13 February 2017
FSI – Fire at Taber Alberta Plant
VICTORIA, BRITISH COLUMBIA, February 13, 2017 – FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE-MKT: FSI, FRANKFURT: FXT), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. On Saturday, February 11th, a fire started in our Taber Alberta plant where all our swimming pool products are manufactured. The building and contents are a total loss. One employee suffered very minor burns. Insurance was in place.
Sales of products made at this plant are between $600,000 and $800,000 annually meaning that the effect on revenue will be about $150 thousand to $200 thousand per quarter until operations are resumed, while the effect on EBITDA and profits will be extremely small.
There will be no effect on production and sales of the NanoChem division nor will WatersavrTM production and sales be affected. 95% of annual sales are through NanoChem and WatersavrTM. Customers of our pool products should contact their sales representative regarding orders that are in place or to be placed.
About Flexible Solutions International
Flexible Solutions International, Inc. (www.flexiblesolutions.com), based in Victoria, British Columbia, is an environmental technology company. The Company’s NanoChem Solutions Inc. subsidiary specializes in biodegradable, water-soluble products utilizing thermal polyaspartate (TPA) biopolymers. TPA beta-proteins are manufactured from the common biological amino acid, L-aspartic and have wide usage including scale inhibitors, detergent ingredients, water treatment and crop enhancement. The other divisions manufacture energy and water conservation products for drinking water, agriculture, industrial markets and swimming pools throughout the world. FSI is the developer and manufacturer of WaterSavrTM, the world’s first commercially viable water evaporation retardant. WaterSavrTM reduces evaporation by up to 30% on reservoirs, lakes, aqueducts, irrigation canals, ponds and slow moving rivers. HeatsavrTM, a “liquid blanket” evaporation retardant for the commercial swimming pool and spa markets, reduces energy costs by 15% to 40% and can result in reduced indoor pool humidity. The Company’s EcosavrTM product targets the residential swimming pool market providing the same savings as HeatsavrTM.
Safe Harbor Provision
The Private Securities Litigation Reform Act of 1995 provides a "Safe Harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward looking statement with respect to events, the occurrence of which involve risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Absolutely! One thing I am surprised about is no one was on their previous conference call. For a company that is profitable you would imagine there would be more interest.
It appears the primary way the communicate with investors are through their filings or calling IR.
Hope all is well!
Flexible Solutions International, Inc. (NYSEMKT:FSI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Flexible Solutions International, Inc is an environmental technology company focusing on the research, development and manufacturing of products that save water and energy. The Company develops and manufactures products such as WaterSavr, Heatsavr and Ecosavr. The Company also offers thermal polyaspartate biopolymers (TPAs) for oil fields, agricultural industry, irrigation, detergents, personal care products and cosmetic products. Flexible Solutions International, Inc is based in Victoria, Canada. “
Separately, TheStreet lowered Flexible Solutions International from a “buy” rating to a “hold” rating in a research report on Friday, December 2nd.
Flexible Solutions International (NYSEMKT:FSI) traded down 2.23% during midday trading on Tuesday, hitting $1.30. 32,094 shares of the company traded hands. The stock has a 50 day moving average of $1.39 and a 200 day moving average of $1.71. Flexible Solutions International has a 12-month low of $0.75 and a 12-month high of $2.41. The stock has a market cap of $14.89 million, a P/E ratio of 8.72 and a beta of 0.99.
A hedge fund recently bought a new stake in Flexible Solutions International stock. Panagora Asset Management Inc. acquired a new position in Flexible Solutions International, Inc. (NYSEMKT:FSI) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 48,964 shares of the company’s stock, valued at approximately $109,000. Panagora Asset Management Inc. owned about 0.43% of Flexible Solutions International as of its most recent filing with the SEC.
Flexible Solutions International Company Profile
Flexible Solutions International, Inc develops, manufactures and markets specialty chemicals, which slow the evaporation of water. The Company operates through two segments: Energy and water conservation products (EWCP), and Biodegradable polymers (BCPAs). The Company’s Energy and water conservation products segment consists of liquid swimming pool blanket, which saves energy and water by inhibiting evaporation from the pool surface, and food-safe powdered form of the active ingredient within the liquid blanket, which is designed to be used in still or slow moving drinking water sources.
Get a free copy of the Zacks research report on Flexible Solutions International (FSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
I plan on sticking around on this board for a while too. I ended up selling what I had previously then bought back in in the low 90's. Anyways, I plan on staying in this stock for a while and slowly accumulate shares since I by no means have large sums of money to invest. I have a buddy that owns a distribution company so I was planning on chatting with him about ROX products.
You all need credit because the conversations you all have among each other are insightful and when compared to other boards are light years beyond in comparison. I appreciate the wealth of knowledge that is shared on this board.
Haha, thanks. I am surprised that you make such quick plays while running a business. I work in the medical field and really appreciate disruptive technologies. Even though I know this type of stock has a particular risk with it I think it could have a quantifiable impact on medical care. There are a few other privately owned companies I follow as well that I wish I could invest in. I'll try to track what your trading style and try to keep up as you/mick all seem fairly prolific on IHUB.
I like your strategy. I just started to invest 7 months ago, been teaching myself as I go along the way. Luckily I am up 30% but missed some opportunities with tax loss selling techniques. I know the market has been a bull market so it's likely helped me along the way. I am not sure if here or email is the best way to pick your mind about how you are trading outside of PMCB but if you are willing to offer me some insight I would take you up on it!
You and I both. I am reading more primary literature and PMCB has solid tech. I also think they have a significant lead on other biologic in this space however this is the make or break it stage for this specific business line. I am not familiar with the other business lines when compared to CIAB.
That you did!- I think PMCB is going to start building a lot of momentum. I am slowly accumulating more and more shares of this. I do believe that it's on the right track and the pivotal study phase is essential.
Just some info:
http://www.nature.com/nrd/journal/vaop/ncurrent/abs/nrd.2016.232.html
http://www.neurotechusa.com/ect-platform.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801806/
https://www.researchgate.net/publication/233540980_Encapsulation_Technology_to_Protect_Probiotic_Bacteria
It looks like the tech is gaining traction again. The last article to me is the most fascinating.
I think you are right. It's a leave and forget it type order. If it gets filled that's sweet however if it does not I have another one in mind I am waiting to come down a little.
Put in an order for .001 :) I hope it gets filled!
This is bleeding like a stuck pig. I guess I will need to load up in the trips and average down.